chr1-11114338-A-G
Variant summary
Our verdict is Pathogenic. Variant got 10 ACMG points: 10P and 0B. PS2_ModeratePS4_ModeratePS3PP2PM2_Supporting
This summary comes from the ClinGen Evidence Repository: The c.7280T>C (NM_004958.4) variant in MTOR is a missense variant predicted to cause substitution of (p.Leu2427Pro). The prevalence of the variant in affected individuals is significantly increased compared with the prevalence in controls (PS4_M; PMIDs: 25799227, 25159823; identified in 2 individuals with neuropathology confirmatory of a malformation of cortical development, 1 tumor sample in the literature and COSMIC). An animal model generated with this variant shows a seizure phenotype which responded to treatment with rapamycin indicating that this variant impacts protein function (PMID:29937275) (PS3_Strong). Testing of unaffected and affected tissue show variable allelic fractions consistent with a post-zygotic event (PS2_Moderate; PMID:25799227). This variant is absent from gnomAD v2.1.1 (PM2_Supporting). MTOR, in which the variant was identified, is defined by the ClinGen Brain Malformations Expert Panel as a gene that has a low rate of benign missense variation and where pathogenic missense variants are a common mechanism of disease (PP2). In summary, this variant meets the criteria to be classified as Pathogenic for mosaic autosomal dominant overgrowth with or without cerebral malformations due to abnormalities in MTOR-pathway genes based on the ACMG/AMP criteria applied, as specified by the ClinGen Brain Malformations Expert Panel: PS4_M, PS3, PS2_M, PM2_P, PP2; 10 points (VCEP specifications version 1; Approved: 1/31/2021) LINK:https://erepo.genome.network/evrepo/ui/classification/CA338380762/MONDO:0016054/018
Frequency
Consequence
NM_004958.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 10 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MTOR | NM_004958.4 | c.7280T>C | p.Leu2427Pro | missense_variant | 53/58 | ENST00000361445.9 | NP_004949.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MTOR | ENST00000361445.9 | c.7280T>C | p.Leu2427Pro | missense_variant | 53/58 | 1 | NM_004958.4 | ENSP00000354558.4 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 31
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Overgrowth syndrome and/or cerebral malformations due to abnormalities in MTOR pathway genes Pathogenic:1
Pathogenic, reviewed by expert panel | curation | ClinGen Brain Malformations Variant Curation Expert Panel | Feb 12, 2022 | The c.7280T>C (NM_004958.4) variant in MTOR is a missense variant predicted to cause substitution of (p.Leu2427Pro). The prevalence of the variant in affected individuals is significantly increased compared with the prevalence in controls (PS4_M; PMIDs: 25799227, 25159823; identified in 2 individuals with neuropathology confirmatory of a malformation of cortical development, 1 tumor sample in the literature and COSMIC). An animal model generated with this variant shows a seizure phenotype which responded to treatment with rapamycin indicating that this variant impacts protein function (PMID: 29937275) (PS3_Strong). Testing of unaffected and affected tissue show variable allelic fractions consistent with a post-zygotic event (PS2_Moderate; PMID: 25799227). This variant is absent from gnomAD v2.1.1 (PM2_Supporting). MTOR, in which the variant was identified, is defined by the ClinGen Brain Malformations Expert Panel as a gene that has a low rate of benign missense variation and where pathogenic missense variants are a common mechanism of disease (PP2). In summary, this variant meets the criteria to be classified as Pathogenic for mosaic autosomal dominant overgrowth with or without cerebral malformations due to abnormalities in MTOR-pathway genes based on the ACMG/AMP criteria applied, as specified by the ClinGen Brain Malformations Expert Panel: PS4_M, PS3, PS2_M, PM2_P, PP2; 10 points (VCEP specifications version 1; Approved: 1/31/2021) - |
Isolated focal cortical dysplasia type II Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Apr 11, 2017 | - - |
CEBALID syndrome Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Equipe Genetique des Anomalies du Developpement, Université de Bourgogne | Sep 01, 2020 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at